Phaseline

Companies › 4D Molecular Therapeutics

4D Molecular Therapeutics: clinical trials, targets and expected readouts

5 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 3, 2 Phase 2; Ophthalmology, Respiratory, Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
4D-150
AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s
VEGFA, VEGFC, VEGFR2Phase 3Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema …Mar 2027
4D-710
AAV gene therapy delivering human CFTR with regulatory domain deletion (CFTRΔR)
CFTRPhase 2Cystic Fibrosis LungJun 2027
4D-110
AAV gene therapy delivering codon-optimized human CHM gene via AAV5 capsid variant (4D-R10
CHMPhase 1ChoroideremiaMay 2027
4D-125
AAV5-delivered codon-optimized human RPGR transgene
RPGRPhase 1X-Linked Retinitis PigmentosaMay 2029
4D-310
AAV gene therapy encoding codon-optimized human GLA transgene
GLAPhase 1Fabry DiseaseJun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT051972704D-150Phase 1Neovascular (Wet) Age-Related Macular DegenerationOphthalmologyMar 2027
NCT044834404D-110Phase 1ChoroideremiaOphthalmologyMay 2027
NCT052482304D-710Phase 2Cystic Fibrosis LungRespiratoryJun 2027
NCT068649884D-150Phase 3Macular Neovascularization Secondary to Age-Related Macular DegenerationOphthalmologyJun 2027
NCT070647594D-150Phase 3Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyNov 2027
NCT078670804D-150Phase 3Diabetic Macular Edema (DME)OphthalmologyJan 2029
NCT059305614D-150Phase 2Diabetic Macular EdemaOphthalmologyFeb 2029
NCT045171494D-125Phase 1X-Linked Retinitis PigmentosaOphthalmologyMay 2029
NCT056295594D-310Phase 1Fabry DiseaseMetabolic and endocrineJun 2030
NCT045197494D-310Phase 1Fabry DiseaseMetabolic and endocrineJun 2030

From the company's SEC filings

Cash and short-term investments of $361m on 2026-06-30; operating cash outflow about $280m a year; runway about 16 months at that burn, to Oct 2027; 2 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CFTR (1) VEGFA (1) VEGFC (1) VEGFR2 (1) CHM (1) RPGR (1) GLA (1)

Companies with the same targets

Vertex Pharmaceuticals Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Beacon Therapeutics Napo Pharmaceuticals ReCode Therapeutics Napo Therapeutics Qanatpharma Krystal Biotech

Companies built like this

Ocugen Opus Genetics Beacon Therapeutics Annexin Pharmaceuticals ProQR Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.